{"name":"Samus Therapeutics, Inc.","slug":"samus-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"zelavespib","genericName":"zelavespib","slug":"zelavespib","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"zelavespib","genericName":"zelavespib","slug":"zelavespib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1JeFhic3p4eTY0eklvSUxHY2F0NTl4R0dDY3NJSHdOdl83SHdVd0lxZUFVSERXYkkyaFpOTTRhakFmOERMNXB0ZEZtTXFONHZ2NVZPSDVEMVAxWkk3?oc=5","date":"2025-04-17","type":"regulatory","source":"EurekAlert!","summary":"Novel radiolabeled antibody developed for diagnosis and treatment of solid tumors - EurekAlert!","headline":"Novel radiolabeled antibody developed for diagnosis and treatment of solid tumors - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPUHhxaGFRWDg0OGxIcXBWWlZreTFab01VRDhtSF9XVjdiQjZhcG5oYWttTmt2bVBvM3VFNWJzalMyWlc0Wms0a0lzX2l3Mm5YcExCN0hLWkktd1ZPcnF3UFNyUDZURksxeHp6eTRCUjc0V1BXTW9HZERUU09IYmZ0RUFtYTNVWDZkWUFsYVplOWFXbHE3R2xpUk9FN0Y1eXBGYUZkZU5pX2xsUTBOQVpDc21GSTNJS2ZIa3JkU0ktRlI4SUZuU1RTQWFNNlJ2bzA2UnBPQkZRaEhIR3FXN2tpUHIzN0xfSEZ5SUowNmVKZXZ4LVFsZmRj?oc=5","date":"2025-02-26","type":"pipeline","source":"PR Newswire","summary":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - PR Newswire","headline":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxORnViXzB3VVFUSjAxaVdiMDNFS2d3b1BJallZZS1LVTBrU3NDampweURKeGVtaE9oS2FPc0M0MXpYdDdRSE8tTHNCZlVFSEk1RTdrU1Qxd3p4eGMxNXlpVWlHUTlrNjV5RkJHdjhWajVnSGxzcm9wV0JkMWtBVXZwQ29qcGZlVVdIcURDdm9MbEFuZ3lENTFua2dRQlUydTZjMnVFS2FXS2I0OUpSU2R0UzBnWmZaVlZza1lnSU5YMm5vU2dBeW81bGN4cW9UY1QtdkNCMWxqMUF5WHZGWVYydDc5RWhHWUFSV0FNZTNPOFgxdw?oc=5","date":"2025-02-20","type":"regulatory","source":"GlobeNewswire","summary":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire","headline":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-02","type":"regulatory","source":"GlobeNewswire","summary":"SERD Market is Predicted to Exhibit Remarkable Growth Owing - GlobeNewswire","headline":"SERD Market is Predicted to Exhibit Remarkable Growth Owing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZ1R2OG0yX293dnl5YVhwS3UtcmtBQ0wzaFFFMVZBcVA0TmFZQnFJUXNKYjBNVEJoMkE1dlFjcXRVRTNhSk8tLUgzZjl3MkJMZFJIOTV4QzdhVWJMUmtqZXQwai1QLXVqNk50cUF4TkJtaDlUOHdkaUFtM3Ixak4tYm5JRjl5VHVJaHloSFFYN25RTkM5S2NvOWlIT250bDA5MEloU2phQm5TZklCdEFzQ2c3ZGdfWHF0eThURTMyOW1LSXRzVGpOaENhWFBzVHNyRzlEamp1RU96bW5vZWc0?oc=5","date":"2024-09-25","type":"pipeline","source":"PR Newswire","summary":"CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - PR Newswire","headline":"CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxOU2FMc093TVVNRW16NDA1Yi1JNHNQdlhSNmhZT2Z3RXNGaDFkS0M0RWVtWjlCbUQtTDRKMWNWcmhCUDd0cVViNk5OeUFQQUZ0WnQ5ejFmc2xqZ1AwZWMyVUZTWU1QVEI0a2w1X0VKOUhRWlFGTkE2QmRReHAwcWpjb1RaMUJ1NHM2MHFteUJ4WHdDal9VR0dnaHkwcWZfUjZ5NElWOFEtOHFwY2p5dXk2Y2JvWFp5OHZwcUJUamVzdUpkSVBJZVlwTEtaaEJWZHk5N3VRVHRzbE5yQ2JnS1lGdWlNLWRxU2tLcGVwUGU3T1hIY3lhVEhRT3VQb01HTkVuNUZ3OFMtZnh5dmp0Qmx6N0p1U1Y5SVNySkZzQXBpUGFER0dCWTFVS0dlNVRrNm8zWWpWVWV1dnJrdUp2eWduMXZ3OA?oc=5","date":"2021-12-01","type":"trial","source":"PR Newswire","summary":"Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells - PR Newswire","headline":"Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOVHl2dXlIaHNyQU1obllsdV9ONENXZTVlbzBYeFNxQUpPcVRBX2FMbnN2TDRrMmVPdG9DSWNoaFBvVGp1NExuWlNkZ01ZYjd2M0FZc1dYOF8zX2ExaHAySHR4aGpfZHYydXkteG5uT0JiWTYzQ1E0REFsQW9fcEtGN2JaVFFuRDItbjVUMVJLdkx0OThtc1I4SXBLR3N5Mk5rVnBQM2FBOVpKTXdjSnE2YnhLSnc2c0tZTUI5SVBXUVg4T3oyY3lOaGZnUDVYQ01ETFhEa2N1dUY0QWZwOTA4V0lCVlFkNktQVklTdWNYbUVBWjBfcWNRbmV0Z2NuSzRyeXRnQ05wMjBzNXFRYVRZ?oc=5","date":"2018-06-13","type":"trial","source":"PR Newswire","summary":"Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis - PR Newswire","headline":"Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPcVNLRHIwendjRW9nNE5tajJnZWxiSC1vV0h2ZFRVNXRzYTRZdFBIOWdaZ3lfTVJFek04RlBUMHpHSmRMUnE1Z1JIQV85N2l6RUFWMFJOQWhfd0JBQlROdU01aVhJbUVWN0xzY1pZQW5KZzR0VVpGUFNzZEg2bkYwY3NOX0JfVWtUazJR?oc=5","date":"2017-01-10","type":"pipeline","source":"Massachusetts Biotechnology Council","summary":"An Open Letter to the BioPharma Community - Massachusetts Biotechnology Council","headline":"An Open Letter to the BioPharma Community","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}